1. JAK/STAT Signaling Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR MAPK/ERK Pathway Stem Cell/Wnt Epigenetics Cell Cycle/DNA Damage Apoptosis
  2. EGFR Akt ERK PARP Survivin
  3. Patritumab

Patritumab  (Synonyms: Human Anti-ERBB3 Recombinant Antibody)

Cat. No.: HY-P99275 Purity: 98.95%
COA

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

For research use only. We do not sell to patients.

CAS No. : 1262787-83-6

Size Price Stock Quantity
1 mg USD 390 In-stock
5 mg USD 975 In-stock
10 mg USD 1560 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Patritumab

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].

Isotype

Human IgG1(K214R) kappa

Recommend Isotype Controls
Species

Human

In Vitro

Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis[1].
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells[1].
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: DiFi-HRG cells
Concentration: 10 μg/mL
Incubation Time: 6 hours
Result: Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.
In Vivo

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice[1].
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)[1]
Dosage: 1 mg/body
Administration: Intraperitoneal injection; twice a week for 4 weeks
Result: Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.
Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Patritumab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Biological Activity
  • Loaded Patritumab on AHC2 biosensor, can bind HER3 Protein, Human (HEK293, His, HY-P72625) with an affinity constant of 1.804E-09 M as determined in BLI assay.
Purity & Documentation

Purity: 98.95%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Patritumab
Cat. No.:
HY-P99275
Quantity:
MCE Japan Authorized Agent: